A Novel Gβγ-Subunit Inhibitor Selectively Modulates μ-Opioid-Dependent Antinociception and Attenuates Acute Morphine-Induced Antinociceptive Tolerance and Dependence

Jennifer L. Mathews  
*St. John Fisher College, jmathews@sjfc.edu*

Alan V. Smrcka

Jean M. Bidlack

How has open access to Fisher Digital Publications benefited you?

Follow this and additional works at: [http://fisherpub.sjfc.edu/pharmacy_facpub](http://fisherpub.sjfc.edu/pharmacy_facpub)

Part of the Pharmacy and Pharmaceutical Sciences Commons

Publication Information


Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit [http://libguides.sjfc.edu/citations](http://libguides.sjfc.edu/citations).

This document is posted at [http://fisherpub.sjfc.edu/pharmacy_facpub/2](http://fisherpub.sjfc.edu/pharmacy_facpub/2) and is brought to you for free and open access by Fisher Digital Publications at St. John Fisher College. For more information, please contact fisherpub@sjfc.edu.
A Novel Gβγ-Subunit Inhibitor Selectively Modulates μ-Opioid-Dependent Antinociception and Attenuates Acute Morphine-Induced Antinociceptive Tolerance and Dependence

Disciplines
Pharmacy and Pharmaceutical Sciences

Comments
Copyright © 2008, Society for Neuroscience. The original publication is available at http://dx.doi.org/10.1523/JNEUROSCI.2326-08.2008
A Novel Gβγ-Subunit Inhibitor Selectively Modulates μ-Opioid-Dependent Antinociception and Attenuates Acute Morphine-Induced Antinociceptive Tolerance and Dependence

Jennifer L. Mathews, Alan V. Smrcka, and Jean M. Bidlack
Department of Pharmacology and Physiology, University of Rochester, School of Medicine and Dentistry, Rochester, New York 14642-8711

The Gβγ subunit has been implicated in many downstream signaling events associated with opioids. We previously demonstrated that a small molecule inhibitor of Gβγ-subunit-dependent phospholipase (PLC) activation potentiated morphine-induced analgesia (Bonacci et al., 2006). Here, we demonstrate that this inhibitor, M119 (cyclohexanecarboxylic acid [2-(4,5,6-trihydroxy-3-oxy-3H-xanthen-9-yl)-(9Cl)], is selective for μ-opioid receptor-dependent analgesia and has additional efficacy in mouse models of acute tolerance and dependence. When administered by an intracerebroventricular injection in mice, M119 caused 10-fold and sevenfold increases in the potencies of morphine and the μ-selective peptide, DAMGO, respectively. M119 had little or no effect on analgesia induced by the κ agonist U50,488 or δ agonists DPDPE or Deltorphin II. Similar results were obtained in vitro, as only activation of the μ-opioid receptor stimulated PLC activation, whereas no effect was seen with the κ- and δ-opioid receptors. M119 inhibited μ-receptor-dependent PLC activation. In studies to further explore the in vivo efficacy of M119, systemic administration M119 also resulted in a fourfold shift increase in potency of systemically administered morphine. Of particular interest, M119 was also able to attenuate acute, antinociceptive tolerance and dependence in mice treated concomitantly with both M119 and morphine. These studies suggest that small organic molecules, such as M119, that specifically regulate Gβγ subunit signaling may have important therapeutic applications in enhancing opioid analgesia, while attenuating the development of tolerance and dependence.

Key words: opioid; Gβγ-subunit; tolerance; dependence; antinociception; mice

Introduction

Opioid analgesics are clinically important for the treatment of moderate to severe pain. The three types of opioid receptor, μ, δ, and κ, are G-protein-coupled receptors that activate Gs, resulting in inhibition of adenylyl cyclase activity (Sharma et al., 1977), activation of inwardly rectifying K+ channels (North et al., 1987), inhibition of voltage-activated Ca2+ channels (Moises et al., 1994), and the activation of mitogen-activated protein kinase, extracellular signal-regulated ERK-1/2 kinases (Law et al., 2004), and phosphatidylinositol (PI)-specific phospholipase C (PLC) (Xie et al., 1999). Recently, the importance of Gβγ-mediated activation of PLC in the potentiation of opioid analgesia has been examined (Xie et al., 1999; Galeotti et al., 2006).

Activation of PLC results in hydrolysis of phosphatidylinositol 4,5-bisphosphate to the two signaling molecules, inositol-1,4,5-trisphosphate, which mobilizes Ca2+ from intracellular stores, and diacylglycerol, which activates protein kinase C (PKC) (Rebecchi and Pentyala, 2000). PLCβ2 and PLCβ3 isoforms are activated by Gβγ and are responsible for phosphatidylinositol (PI) hydrolysis stimulated by Gs-coupled receptors, with PLCβ2 being expressed primarily in hematopoietic cells (Rhee and Bae, 1997).

Previous data from our laboratories suggested that pharmacological inhibition of PLCβ3 might enhance opioid-induced antinociception (Xie et al., 1999). In these experiments with PLCβ3 knock-out mice, the mice lacking PLCβ3 had a 10-fold potentiation in morphine-induced antinociception compared with control animals. This finding was one of the first indications that this pathway may be an important regulator of opioid signaling and subsequent analgesic responsiveness, and indicated that targeting PLCβ3 or PLCβ3 regulation pharmacologically could influence opioid efficacy.

Recently, we reported on a series of novel Gβγ inhibitors (Bonacci et al., 2006). From screening of a small molecule library, several compounds were found that bound to Gβγ subunits and selectively inhibited Gβγ subunit signaling. The lead compound in the series, M119 (cyclohexanecarboxylic acid [2-(4,5,6-
trihydroxy-3-oxo-3β-xanthene-9-yl)-(9Cl)), had high affinity for the Gβγ subunit and was an inhibitor of PLCβ3 signaling in vitro. In vivo, coadministration of M119 (100 nmol, intracerebroventricular (i.c.v.)]) with graded doses of morphine (i.c.v.) resulted in a 10-fold leftward shift in the morphine antinociceptive dose–response curve (Bonacci et al., 2006), similar to the shift that had been seen with the PLCβ3 knock-out mice (Xie et al., 1999). Administration of M119 with morphine in the PLCβ3 knock-out mice had no additional effect (Bonacci et al., 2006), further supporting the hypothesis that the mechanism of action for M119 was through the attenuation of opioid-induced activation of PLCβ3 by Gβγ. It is important to note that morphine still produced an analgesic response in the animals which had been administered M119, suggesting that regulation of other Gβγ targets was still intact. This would be of particular importance in the activation of inwardly rectifying K+ channels, which are mediated by Gβγ and thought to play an important role in antinociception.

Selectively inhibiting downstream signaling from the Gβγ subunit, with a small molecule inhibitor, is a novel approach to targeting only a pathway of interest, while leaving the rest of the signaling machinery intact. The goal of this current study was to determine the effect M119 would have in vivo, not only on antinociception mediated by all three opioid receptors, but also in models of acute analgesic tolerance and dependence.

Materials and Methods

Animals. Male, ICR mice (20–30 g) (Harlan Industries) were housed in groups of five with food and water available ad libitum before any procedures. Animals were maintained on a 12 h light/dark cycle in a temperature-controlled animal colony. Studies were performed in accordance with the Policies on the Use of Animals in Neuroscience Research.

Chemicals. M119 (Fig. 1) was obtained from the chemical diversity set (reference number NSC 119910).

Figure 1. Chemical structure of the novel Gβγ-inhibitor M119, which was obtained from the NCI diversity set.
were immediately placed in a clear cylinder and observed for 15 min. The number of vertical jumps was recorded during this time. To test whether M119 affected morphine physical dependence, the same treatment as described above was used with M119 (100 nmol, i.c.v.) being administered 30 min before the administration of naloxone.

Receptor binding assays. The receptor binding assay was performed with membranes from hMOR-CHO cells using the \( \mu \)-selective radioligand \(^3\)H]DAMGO. Binding was performed in 50 mM Tris-HCl, pH 7.5, at 25°C for 60 min with varying concentrations of M119. Membrane protein (50 \( \mu \)g of hMOR-CHO) was incubated in 50 mM Tris-HCl, pH 7.5 in a final volume of 1 ml with 0.25 nm \(^3\)H]DAMGO and varying concentrations of M119. Nonspecific binding was determined in the presence of 10 \( \mu \)M naloxone. After a 60 min incubation at 25°C, the membranes were filtered onto No. 32 glass by vacuum filtration, followed by three washes with 3 ml of ice-cold 50 mM Tris-HCl, pH 7.5. Samples were counted in 2 ml of Scintsafe 30% scintillation fluid.

cAMP assay. To measure cAMP, hMOR-CHO cells were grown in 12-well plates and incubated with 1 \( \mu \)M forskolin, 100 \( \mu \)M isobutylmethylxanthine (IBMX), and varying concentrations of M119, in serum-free DMEM media for 20 min. After the incubation, the plates were immediately placed on ice and the cells were washed with PBS and lysed with 0.1 N HCl. cAMP was extracted and quantified, following the manufacturer’s instructions, using the cAMP EIA direct assay kit from Assay Design. Data are represented as percentage of cAMP over control.

Statistical analysis. Data from dose–response experiments were fitted to a sigmoidal dose–response model using nonlinear regression analysis, and ED\(_{50}\) values and 95% confidence limits (CL) were calculated. A shift in the dose–response curve was determined from the ED\(_{50}\) values. To assess whether the ED\(_{50}\) or IC\(_{50}\) values for two dose–response or concentration–response curves were significantly different, an F test was performed (GraphPad Prism 4.03). Values are reported as two-tailed \( p \) values. Statistical significance was set at \( p < 0.05 \). All data points are the mean of 7–10 mice, with SEM represented by error bars. Statistical analysis of the acute dependence data and inositol phosphate data used the Student’s \( t \) test.

Results

The \( G\beta\gamma \) inhibitor, M119, potentiated \( \mu \)-opioid receptor-mediated antinociception

Previous data from our lab demonstrated that PLC\(_{\beta3}\), a \( G\beta\gamma \) subunit-regulated enzyme, was a negative modulator of \( \mu \)-opioid-dependent signaling (Xie et al., 1999). We therefore predicted that inhibiting \( G\beta\gamma \)-dependent PLC\(_{\beta3}\) activation would potentiate \( \mu \)-opioid-mediated antinociception, in a manner similar to the PLC\(_{\beta3}\) knock-out studies (Xie et al., 1999; Bonacci et al., 2006). Previously, we observed that coadministration of M119 (Fig. 1) with morphine resulted in a significant (\( p < 0.001 \)), 10-fold potentiation in morphine-mediated antinociception (Bonacci et al., 2006) (Fig. 2A). To determine whether the effects of M119 were specific to morphine, M119 was also administered with agonists selective for the \( \mu \), \( \kappa \), and \( \delta \) receptors. Co-administration of M119 and the \( \mu \)-selective agonist, DAMGO, resulted in a sevenfold leftward shift in the DAMGO dose–response curve when compared with DAMGO alone (\( p < 0.001 \)) (Fig. 2B). DAMGO alone produced an ED\(_{50}\) value and 95% CL of 0.07 nmol (0.03–0.17 nmol), whereas DAMGO and M119 resulted in an ED\(_{50}\) value and 95% CL of 0.01 nmol (0.005–0.03 nmol). A modest, twofold, shift was observed in the dose–response curve of the \( \kappa \)-selective agonist, U50,488, when administered with M119 (\( p < 0.01 \)) (Fig. 3A). The ED\(_{50}\) values for U50,488 alone and U50,488 with M119 were 37 nmol (29–47 nmol) and 17 nmol (9.4–31 nmol), respectively. M119 did not potentiate antinociception mediated through either \( \delta \), or \( \delta \), receptor. The ED\(_{50}\) values for the \( \delta \)-specific agonist, DPDPE, alone or with M119 did not change significantly, 6.5 nmol (2.6–16 nmol) and 5.4 nmol (2.6–11 nmol), respectively (Fig. 3B). The \( \delta \)-selective agonist, Deltorphin II, produced an ED\(_{50}\) value of 11 nmol (5.5–23 nmol) which was unchanged in the presence of M119, 11 nmol (5.1–23 nmol) (Fig. 3C). Administration of M119 alone had no effect on baseline tail-withdrawal latencies (Bonacci et al., 2006). These experiments demonstrated that M119 selectively potentiated \( \mu \)-opioid-dependent antinociception.

To determine whether M119 would be effective after systemic administration, M119 was administered i.p. followed immediately with a s.c. injection of morphine. Systemic administration of morphine alone produced an ED\(_{50}\) value of 5.0 mg/kg (2.9–8.4 mg/kg), which was shifted fourfold to the left in the presence of M119, producing an ED\(_{50}\) value of 1.3 mg/kg (0.59–2.8 mg/kg) (\( p < 0.001 \)) (Fig. 4).

M119 inhibition of IP production mediated by the \( \mu \)-opioid receptor

We previously proposed that the potentiation in morphine-induced antinociception was caused by M119 inhibition of \( G\beta\gamma \)-dependent PLC\(_{\beta3}\) (Bonacci et al., 2006). To demonstrate that M119 blocked \( \mu \)-opioid receptor-dependent PLC activation, we measured morphine- and DAMGO-dependent total inositol phosphate (IP) production in hMOR-CHO cells. Both DAMGO (10 \( \mu \)M) and morphine (10 \( \mu \)M) significantly increased total IP measured compared with control, with a fourfold and threefold increase, respectively (\( p < 0.01 \)) (Fig. 5A). This increase was significantly attenuated with the addition of the \( G\beta\gamma \) inhibitor, M119 (10 \( \mu \)M) (\( p < 0.05 \)), whereas M119 had no effect by itself. The \( \mu \)-selective antagonist, B-FNA also attenuated DAMGO- and morphine-dependent IP production (Fig. 5A) (\( p < 0.05 \)). The effect of M119 on DAMGO-stimulated IP generation was concentration dependent (Fig. 5B). Maximal M119 effects were observed at 10 \( \mu \)M (\( p < 0.05 \)) and 30 \( \mu \)M (\( p < 0.01 \)). The \( \kappa \)-selective agonist, U50,488 (10 \( \mu \)M) and the \( \delta \)-selective agonists, DPDPE (10 \( \mu \)M) had no effect on IP production alone or in the presence of M119 in the hMOR-CHO cells (data not shown). These data demonstrate that the \( \mu \)-opioid receptor can stimulate PLC activation and that this coupling was blocked by M119.

To determine whether other opioid receptors couple to PLC activation, we examined opioid receptor-dependent IP generation in hDOR-CHO and hKOR-CHO cells. In the hDOR-CHO cells neither DPDPE (10 \( \mu \)M) or Deltorphin II (10 \( \mu \)M) significantly increased IP generation over control treated cells (Fig. 5C).
Treatment with M119 (10 \( \mu \)M) and the \( \delta \)-selective antagonist, naltrindole (100 \( \mu \)M) also had no significant effect (Fig. 5C). Treatment with U50,488 (10 \( \mu \)M), with or without M119 (10 \( \mu \)M) or nor-BNI (10 \( \mu \)M), the \( \kappa \)-selective antagonist, in the hKOR-CHo cells had no significant effect on IP production over control treated cells (Fig. 5D). Importantly, the levels of opioid receptors were the same for all three cell lines (\( B_{\text{max}} \) values not significantly different, data not shown). These \( \textit{in vitro} \) data correlate with the effects of M119 \textit{in vivo}, where only in the mice treated with the \( \mu \)-preferring compounds was a significant potentiation in antinociception observed. It is possible that the selective effects of M119 observed \textit{in vivo} on \( \mu \)-opioid receptor-dependent antinociception are the result of selective coupling of \( \mu \)-opioid receptor to \( \text{G}\beta\gamma \)-dependent PLC activation.

**Effect of M119 on acute morphine antinociceptive tolerance**

As an initial test of the efficacy of M119 in reducing the development of morphine antinociceptive tolerance, an acute tolerance assay was performed. We used this assay to measure tolerance because it requires considerably less compound than traditional tolerance paradigms, while still yielding reliable results. The antinociceptive effect of repeated (0, 2, 4, 6 h) doses (1–10 nmol) of morphine and the development of acute antinociceptive tolerance are shown in Figure 6A. Morphine produced dose-dependent antinociception in the 55°C warm-water tail-flick test. All data points are the mean of 7–10 mice, with SEM represented by error bars. Coadministration of M119 with morphine greatly attenuated acute morphine antinociceptive tolerance (Fig. 6B). The \( ED_{50} \) values remained virtually unchanged, with no statistical difference, from time 0, 0.16 nmol (0.02–1.3 nmol) to the 6 h time point, 0.22 nmol (0.008–5.7 nmol). Control mice were treated under the same injection protocol, however, received only vehicle. No significant change from baseline tail-withdrawal values were observed for any of the control mice at any of the times tested (data not shown), indicating that the procedure used in the acute tolerance protocol was not contributing to the data which was observed.

**Effect of M119 on acute morphine physical dependence**

In an acute model of morphine dependence, mice were treated with morphine (100 mg/kg, s.c., −4 h), followed by M119 (100 mg/kg, i.p.) and then morphine (100 mg/kg, i.p.) after each 4 h injection. Mice treated with morphine and M119 showed significantly less opioid withdrawal symptoms than the morphine only group (Fig. 6C). This result is consistent with the observation that M119 attenuates morphine withdrawal symptoms in rats (35). Indirect evidence for this effect comes from a study showing that morphine withdrawal symptoms could be attenuated by the \( \delta \)-opioid receptor antagonist, naltrindole (100 mg/kg, i.p.) (36).
cantly inhibit \(^{3}H\)DAMGO binding to the \(\mu\)-opioid receptor at any concentration tested (Fig. 8A).

It is well established that all three types of opioid receptors activate \(G_{i}\), resulting in inhibition of adenyl cyclase activity (Sharma et al., 1977; Childers, 1991). Therefore, if the receptor is in fact signaling effectively, this would be reflected as an inhibition of cAMP levels. Previous in vitro studies with M119 had suggested that the compound did not prevent the heterotrimeric G-protein from reassembling (Bonacci et al., 2006). However, it was unclear whether M119 would potentiate the downstream opioid effects on cAMP. hMOR-CHO cells were treated with forskolin and IBMX to stimulate cAMP production. The \(\mu\)-selective agonist, DAMGO, concentration-dependently inhibited cAMP levels with an IC\(_{50}\) value of 24 ± 3.6 nM (Fig. 8B). Concomitant treatment of cells with DAMGO and M119 (10 \(\mu\)M) did not potentiate this effect as shown by the IC\(_{50}\) value of 26 ± 2.9 nM (Fig. 8B). A similar effect was observed with morphine (data not shown). The general opioid antagonist, naloxone, reversed the effects of both DAMGO and morphine indicating that both agonists were inhibiting cAMP production through an opioid-mediated pathway (data not shown).

**Discussion**

In the current study, our laboratory took the novel approach of using a \(G_{\beta}\gamma\) inhibitor to influence the efficacy and potency of morphine in several animal models of \(\mu\)-opioid receptor function. Our fundamental hypothesis for the mechanism of action of this compound is based on studies conducted by Xie et al. (1999) demonstrating that the \(G_{\beta}\gamma\)-dependent enzyme, PLC\(_{\beta}\), was a negative modulator of \(\mu\)-opioid receptor signaling both in PLC\(_{\beta}\) knock-out mice and in dorsal root ganglion neurons. We demonstrated previously that the \(G_{\beta}\gamma\) inhibitor, M119, inhibited the activation of PLC\(_{\beta}\) by \(G_{\beta}\gamma\) in vitro and that concomitant administration of this novel compound with morphine in vivo resulted in a 10-fold shift in morphine analgesic potency, virtually identical, to data from the PLC\(_{\beta}\) knock-out studies (Xie et al., 1999; Bonacci et al., 2006). In addition, M119 had no effect in PLC\(_{\beta}\) knock-out mice, further supporting in vitro evidence that M119 was blocking the binding of \(G_{\beta}\gamma\) to PLC\(_{\beta}\) (Bonacci et al., 2006).

Here, we explored further the specificity and underlying mechanisms of action of M119 in potentiating analgesia as well as presented evidence extending the potential therapeutic efficacy of this approach.

**M119 displayed \(\mu\)-opioid receptor selectivity in vivo**

Increased analgesic potency was observed in mice treated with M119 and morphine and also M119 and the receptor-selective agonist, DAMGO. Minimal effects were observed with \(\kappa\)- and

**Effects of M119 on opioid receptor binding and downstream signaling**

It was important to demonstrate that increasing concentrations of M119 did not inhibit the ability of an opioid agonist to bind the receptor. Receptor binding assays were performed to address whether M119 mediated its effects through direct binding and activation of the opioid receptors. Increasing concentrations of M119 were incubated with the \(\mu\)-selective peptide \(^{3}H\)DAMGO in membranes from hMOR-CHO cells. M119 did not signifi-
dependent feedback pathway observed for the 
activate the same PLC isoforms, or are not acting in the same PLC pathway. It is for this reason that M119 lacks efficacy with these agonists, U50,488, DPDE, and Deltorphin II. These studies indicated that M119 was selective, in vitro, for the potentiation of μ-mediated analgesia. Similar results were obtained from the in vitro IP assay, with only the μ agonists, DAMGO and morphine, stimulating IP generation which was inhibited by M119. We propose that the generation of IP3 and DAG along with activation of PKC may be important for the development of opioid tolerance and dependence. Inhibitors of PLC downstream signaling and the role of phospholipids in tolerance and dependence

There is evidence that the PLC pathway can influence the development of opioid tolerance and dependence. Inhibitors of PLC (Smith et al., 1999), IP3 receptors (Smith et al., 1999), and PKC (Bilsky et al., 1996; Smith et al., 1999; Bohn et al., 2002) all attenuated morphine tolerance. PKC knock-out animals also exhibited attenuated morphine tolerance (Zeitz et al., 2001). It has also been suggested that generation of IP3 and DAG along with activation of PKC may be important for the development of opioid dependence (Fundytus and Codere, 1996; Smith et al., 1999). In the current studies, M119 attenuated both acute antinociceptive tolerance and dependence, but which of these specific mechanisms downstream of Gβγ-dependent PLCβ3 regulation are responsible for these effects remains to be defined. Additionally, it will be important to study the effect of M119 on chronic morphine-antinociceptive tolerance and dependence.

Specificity and underlying mechanisms of action of M119 in vitro

Previous studies from our lab tested the effects of differentially targeting Gβγ signaling in intact cells. M119 was shown to inhibit activation of phosphoinositide 3 kinase γ (PI3Kγ) and FMLP-induced Ca2+ increases in differentiated HL-60 leukocytes (Bonacci et al., 2006). The fMLP receptor couples to Gi in the HL-60 cells. Importantly, M119 had no effect on carbachol-dependent increases in Ca2+ in HEK293 cells stably expressing the Gq-linked M3-muscarinic receptor, confirming a specific effect of M119 on Gβγ-dependent Ca2+ mobilization (Bonacci et al., 2006). These data suggest that M119 was in fact penetrating into the cell to produce an effect through a Gγ-mediated mechanism. Our current studies demonstrated that M119 did not inhibit [3H]DAMGO binding to the μ-opioid receptor at any concentration tested. As a means to address whether the receptor was signaling as expected, we performed a cAMP assay. The IC50 value for DAMGO was not significantly changed in the presence

![Figure 6](image1.png)

**Figure 6.** Effect of M119 on acute morphine antinociceptive tolerance. In an acute model of morphine antinociceptive tolerance, morphine was administered at times 0, 2, 4, 6 h (4). At 4 h, significant tolerance (p < 0.01) had developed as measured by an eightfold shift in the ED50 value and by 6 h, a 16-fold shift in the ED50 value was measured (p < 0.001). Concomitant administration of M119 (100 nmol, i.c.v.) and graded doses of morphine attenuated acute morphine antinociceptive tolerance at all time points tested (B). Both compounds were administered at times 0, 2, 4, 6 h. No significant change in the ED50 values was determined. Antinociception was assessed 20 min after each injection in the 55°C tail-flick test. Control mice had no change from baseline tail-withdrawal latencies at any of the time points tested (data not shown).

![Figure 7](image2.png)

**Figure 7.** Effect of M119 on morphine-induced physical dependence. In a measure of acute morphine dependence, mice were administered morphine (100 mg/kg, i.c., −4 h) and withdrawal was precipitated by injection of naloxone (10 mg/kg, i.p.). Withdrawal jumping was counted for 15 min after antagonist injection. Injection of M119 (100 nmol, i.c.v.) 30 min before the injection of naloxone resulted in significantly less vertical jumps than naloxone alone (*p < 0.05).

Figure 8. Effect of M119 on [3H]DAMGO binding to the μ-opioid receptor (A) and on DAMGO-induced inhibition of cAMP levels (B). hMOR-CHO membranes were incubated with 0.25 nM [3H]DAMGO and varying concentrations of M119 as described in Materials and Methods. M119 did not significantly inhibit [3H]DAMGO binding to the hMOR (A). DAMGO inhibited forskolin-stimulated cAMP production and this effect was not potentiated by the addition of the Gβγ inhibitor, M119 (B). hMOR-CHO cells were treated with varying concentrations of DAMGO along with 10 μM forskolin and 100 μM IBMX, with and without 10 μM M119. DAMGO dose-dependently inhibited cAMP (IC50 = 24 ± 3.6 nM), and concomitant treatment of cells with DAMGO and 10 μM M119 did not potentiate this effect (IC50 = 26 ± 2.9 nM).
of M119. Additionally, M119 produced a concentration-dependent inhibition of IP generation in hMOR-CHO cells treated with either DAMGO or morphine.

In conclusion, we demonstrated that selectively inhibiting Gβγ signaling represents a novel approach to target only the effector of interest, in this case, PLCβ3, while leaving other signaling pathways intact. This approach represents a novel strategy for potentiating opioid efficacy and also attenuating morphine tolerance and dependence.

References